$NOTE

FiscalNote Holdings, Inc. (NOTE): Results of Operations and Financial Condition

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 note-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FiscalNote Reports Second Quarter 2026 Financial Results Total Revenue In Line with Guidance; Adjusted EBITDA Slightly Below Guidance; Establishes Q3 2026 Forecast and Revises FY26 Guidance Company To Host Conference Call Tod

Original reporting
Published Aug 10, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$NOTE
Neutral
medium confidence
Mentioned
$NOTE
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NOTENeutralMed
01

Why it matters

The key trading inputs are the revised FY26 revenue and adjusted EBITDA ranges, the initial Q3 adjusted EBITDA forecast, and the KPI mix showing NRR stabilization alongside ARR contraction and higher operating expenses driven by a goodwill impairment charge.

02

Market read

Fresh guidance and KPI updates can drive repricing for an OTC growth name, especially around EBITDA ramp credibility and retention durability.

03

What to watch

Non-subscription revenue weakness and elongated sales cycles are explicitly cited; traders may underweight how much of the EBITDA ramp depends on back-half restructuring benefits.

Relevance 7/10Novelty 8/10Timing: after-hours filing today, guidance update for FY26 and Q3

Background

This is an SEC 8-K (Item 2.02) with Exhibit 99.1 covering FiscalNote’s Q2 2026 financial results, operational updates, and updated FY2026 plus initial Q3 2026 forecasts.

Company-level read

Ticker impact

$NOTENeutralMedium confidence
Context

FiscalNote reported Q2 2026 results and updated FY2026 guidance, including adjusted EBITDA below guidance and a new Q3 forecast.

Expected impact

Likely choppy reaction risk, with upside bias if investors focus on NRR stabilization and EBITDA ramp, downside if they focus on ARR decline and lower FY EBITDA.

Evidence & confidence

The filing provides fresh, decision-relevant numbers: Q2 revenue and adjusted EBITDA vs guidance, NRR improvement to 98%, ARR down ~13%, and revised FY26 revenue and adjusted EBITDA ranges plus an initial Q3 EBITDA forecast.

Market effects

AI policy and regulatory intelligence peers may see read-across on enterprise retention and public-sector spending sensitivity.

Primarily US public-sector and federal spending sensitivity highlighted by management.

Global enterprise adoption of PolicyNote MCP APIs (e.g., Siemens) supports international demand narrative, but macro caution remains US-tilted.

Counterpoint

NRR improvement may not offset the magnitude of ARR decline and the non-cash goodwill impairment, so the market may discount stabilization as insufficient.

Key entities

  • FiscalNote Holdings, Inc.

    OTC-listed company reporting Q2 2026 results and updating FY2026 and Q3 2026 guidance.

  • Key Compton

    CEO and President appointed in June 2026, commenting on NRR stabilization and operating discipline.

  • Siemens

    Named as licensing PolicyNote MCP APIs and adopting agentic API offerings in the quarter.

Related articles

$HNRGMed

HALLADOR ENERGY CO (HNRG): Results of Operations and Financial Condition

HALLADOR ENERGY CO (HNRG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hnrg-20260810xex99d1.htm EX-99.1 EXHIBIT 99.1 ​ Hallador Reports Q2 2026 Results; Gas Project Budget Reduced Below $800 Million ​ - Turtle Creek COD Expedited to the Second Half of 2028 - ​ - Contracted Forward Sales Reach $2.4 Billion at the Segment Level - ​ - Managem

$HLIOHigh

HELIOS TECHNOLOGIES, INC. (HLIO): Results of Operations and Financial Condition

HELIOS TECHNOLOGIES, INC. (HLIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hlio-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 NEWS RELEASE 35 m+ FOR IMMEDIATE RELEASE Helios Technologies Reports Second Quarter 2026 Results; Profitable Sales Growth Momentum Continues, Raising Full Year 2026 Outlook • Grew 2Q26 sales to $232 million, up 9% over prior

$BCSFMed

Bain Capital Specialty Finance, Inc. (BCSF): Results of Operations and Financial Condition

Bain Capital Specialty Finance, Inc. (BCSF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bcsf-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Bain Capital Specialty Finance, Inc. Bain Capital Specialty Finance, Inc. Announces June 30, 2026 Financial Results and Declares Third Quarter 2026 Dividend of $0.42 per Share BOSTON – August 10, 2026 – Bain Capital Specialty

$PRPLMed

Purple Innovation, Inc. (PRPL): Results of Operations and Financial Condition

Purple Innovation, Inc. (PRPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030125701ex99-1.htm PRESS RELEASE DATED AUGUST 10, 2026, REGARDING FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026 Exhibit 99.1 Purple Innovation Reports Second Quarter 2026 Results Showroom Revenue Up 16.6% and Comparable Revenue Up 18% GAAP Net Loss of

$ARQMed

Arq, Inc. (ARQ): Results of Operations and Financial Condition

Arq, Inc. (ARQ) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a991pressreleaseq22026_081.htm EX-99.1 Document Exhibit 99.1 Arq Reports Second Quarter 2026 Results Generated revenue of approximately $30 million, up 5% Reported Adjusted EBITDA (1) of approximately $5.8 million, up 59% on prior year period 9 th consecutive quarter of

$HIMSMedAI 8/10

Why is Hims & Hers Health stock sliding today?

Hims & Hers Health shares fell about 1.5% in after-hours after Q2 2026 results. Revenue rose to $753M (+38% YoY) but EPS was a loss of -$0.37 versus -$0.05 expected, tied to gross margin contracting 12 points from a shift from compounded to branded GLP-1. The company raised FY2026 revenue to $3.1B-$3.3B and Q3 guidance to $880M-$900M, but legal and regulatory overhangs and softer GLP-1 billing weighed.